Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein

Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein. Chukwudozie, O., Gray, C., Fagbayi, T., Chukwuanukwu, R., Oyebanji, V., Bankole, T., Adewole, R., & Daniel, E. PLoS ONE, 2021.
doi abstract bibtex

Developing an efficacious vaccine for SARS-CoV-2 infection is critical to stemming COVID- 19 fatalities and providing the global community with immune protection. We have used a bioinformatic approach to aid in designing an epitope peptide-based vaccine against the spike protein of the virus. Five antigenic B cell epitopes with viable antigenicity and a total of 27 discontinuous B cell epitopes were mapped out structurally in the spike protein for antibody recognition. We identified eight CD8+ T cell 9-mers and 12 CD4+ T cell 14-15-mer as promising candidate epitopes putatively restricted by a large number of MHC I and II alleles, respectively. We used this information to construct an in silico chimeric peptide vaccine whose translational rate was highly expressed when cloned in pET28a (+) vector. With our In silico test, the vaccine construct was predicted to elicit high antigenicity and cell-mediated immunity when given as a homologous prime-boost, triggering of toll-like receptor 5 by the adjuvant linker. The vaccine was also characterized by an increase in IgM and IgG and an array of Th1 and Th2 cytokines. Upon in silico challenge with SARS-CoV-2, there was a decrease in antigen levels using our immune simulations. We, therefore, propose that potential vaccine designs consider this approach. Copyright:

@article{Chukwudozie2021a,
abstract = {Developing an efficacious vaccine for SARS-CoV-2 infection is critical to stemming COVID- 19 fatalities and providing the global community with immune protection. We have used a bioinformatic approach to aid in designing an epitope peptide-based vaccine against the spike protein of the virus. Five antigenic B cell epitopes with viable antigenicity and a total of 27 discontinuous B cell epitopes were mapped out structurally in the spike protein for antibody recognition. We identified eight CD8+ T cell 9-mers and 12 CD4+ T cell 14-15-mer as promising candidate epitopes putatively restricted by a large number of MHC I and II alleles, respectively. We used this information to construct an in silico chimeric peptide vaccine whose translational rate was highly expressed when cloned in pET28a (+) vector. With our In silico test, the vaccine construct was predicted to elicit high antigenicity and cell-mediated immunity when given as a homologous prime-boost, triggering of toll-like receptor 5 by the adjuvant linker. The vaccine was also characterized by an increase in IgM and IgG and an array of Th1 and Th2 cytokines. Upon in silico challenge with SARS-CoV-2, there was a decrease in antigen levels using our immune simulations. We, therefore, propose that potential vaccine designs consider this approach. Copyright:},
author = {Chukwudozie, O.S. and Gray, C.M. and Fagbayi, T.A. and Chukwuanukwu, R.C. and Oyebanji, V.O. and Bankole, T.T. and Adewole, R.A. and Daniel, E.M.},
doi = {10.1371/journal.pone.0248061},
journal = {PLoS ONE},
number = {3 March},
title = {{Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein}},
volume = {16},
year = {2021}
}

Downloads: 0

{"_id":"QBvxaLuf4DJy7EjEk","bibbaseid":"chukwudozie-gray-fagbayi-chukwuanukwu-oyebanji-bankole-adewole-daniel-immunoinformaticsdesignofamultimericepitopepeptidebasedvaccinetargetingsarscov2spikeglycoprotein-2021","author_short":["Chukwudozie, O.","Gray, C.","Fagbayi, T.","Chukwuanukwu, R.","Oyebanji, V.","Bankole, T.","Adewole, R.","Daniel, E."],"bibdata":{"bibtype":"article","type":"article","abstract":"Developing an efficacious vaccine for SARS-CoV-2 infection is critical to stemming COVID- 19 fatalities and providing the global community with immune protection. We have used a bioinformatic approach to aid in designing an epitope peptide-based vaccine against the spike protein of the virus. Five antigenic B cell epitopes with viable antigenicity and a total of 27 discontinuous B cell epitopes were mapped out structurally in the spike protein for antibody recognition. We identified eight CD8+ T cell 9-mers and 12 CD4+ T cell 14-15-mer as promising candidate epitopes putatively restricted by a large number of MHC I and II alleles, respectively. We used this information to construct an in silico chimeric peptide vaccine whose translational rate was highly expressed when cloned in pET28a (+) vector. With our In silico test, the vaccine construct was predicted to elicit high antigenicity and cell-mediated immunity when given as a homologous prime-boost, triggering of toll-like receptor 5 by the adjuvant linker. The vaccine was also characterized by an increase in IgM and IgG and an array of Th1 and Th2 cytokines. Upon in silico challenge with SARS-CoV-2, there was a decrease in antigen levels using our immune simulations. We, therefore, propose that potential vaccine designs consider this approach. Copyright:","author":[{"propositions":[],"lastnames":["Chukwudozie"],"firstnames":["O.S."],"suffixes":[]},{"propositions":[],"lastnames":["Gray"],"firstnames":["C.M."],"suffixes":[]},{"propositions":[],"lastnames":["Fagbayi"],"firstnames":["T.A."],"suffixes":[]},{"propositions":[],"lastnames":["Chukwuanukwu"],"firstnames":["R.C."],"suffixes":[]},{"propositions":[],"lastnames":["Oyebanji"],"firstnames":["V.O."],"suffixes":[]},{"propositions":[],"lastnames":["Bankole"],"firstnames":["T.T."],"suffixes":[]},{"propositions":[],"lastnames":["Adewole"],"firstnames":["R.A."],"suffixes":[]},{"propositions":[],"lastnames":["Daniel"],"firstnames":["E.M."],"suffixes":[]}],"doi":"10.1371/journal.pone.0248061","journal":"PLoS ONE","number":"3 March","title":"Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein","volume":"16","year":"2021","bibtex":"@article{Chukwudozie2021a,\nabstract = {Developing an efficacious vaccine for SARS-CoV-2 infection is critical to stemming COVID- 19 fatalities and providing the global community with immune protection. We have used a bioinformatic approach to aid in designing an epitope peptide-based vaccine against the spike protein of the virus. Five antigenic B cell epitopes with viable antigenicity and a total of 27 discontinuous B cell epitopes were mapped out structurally in the spike protein for antibody recognition. We identified eight CD8+ T cell 9-mers and 12 CD4+ T cell 14-15-mer as promising candidate epitopes putatively restricted by a large number of MHC I and II alleles, respectively. We used this information to construct an in silico chimeric peptide vaccine whose translational rate was highly expressed when cloned in pET28a (+) vector. With our In silico test, the vaccine construct was predicted to elicit high antigenicity and cell-mediated immunity when given as a homologous prime-boost, triggering of toll-like receptor 5 by the adjuvant linker. The vaccine was also characterized by an increase in IgM and IgG and an array of Th1 and Th2 cytokines. Upon in silico challenge with SARS-CoV-2, there was a decrease in antigen levels using our immune simulations. We, therefore, propose that potential vaccine designs consider this approach. Copyright:},\nauthor = {Chukwudozie, O.S. and Gray, C.M. and Fagbayi, T.A. and Chukwuanukwu, R.C. and Oyebanji, V.O. and Bankole, T.T. and Adewole, R.A. and Daniel, E.M.},\ndoi = {10.1371/journal.pone.0248061},\njournal = {PLoS ONE},\nnumber = {3 March},\ntitle = {{Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein}},\nvolume = {16},\nyear = {2021}\n}\n","author_short":["Chukwudozie, O.","Gray, C.","Fagbayi, T.","Chukwuanukwu, R.","Oyebanji, V.","Bankole, T.","Adewole, R.","Daniel, E."],"key":"Chukwudozie2021a","id":"Chukwudozie2021a","bibbaseid":"chukwudozie-gray-fagbayi-chukwuanukwu-oyebanji-bankole-adewole-daniel-immunoinformaticsdesignofamultimericepitopepeptidebasedvaccinetargetingsarscov2spikeglycoprotein-2021","role":"author","urls":{},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-9gwO2GBrWfUK-fFo05cgfzXdRK_w9xL","dataSources":["9bX4N36CTXtCXNFMd","wrEvssexmuYudwQw9","6GMFi5DCojy3jHY44"],"keywords":[],"search_terms":["immuno","informatics","design","multimeric","epitope","peptide","based","vaccine","targeting","sars","cov","spike","glycoprotein","chukwudozie","gray","fagbayi","chukwuanukwu","oyebanji","bankole","adewole","daniel"],"title":"Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein","year":2021}